BioCryst Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 04/26/2024
BioCryst Pharmaceuticals Stock Forecast and Price Target
The average price target of $10.50 for BioCryst Pharmaceuticals's stock set by two distinguished analysts in recent weeks would represent a potential upside of approximately 152.4% from the last closing price in April, 2024 if reached by the end of the year. This potential increase is based on a high estimate of $20.00 and a low estimate of $6.00. If interested in BCRX stock, you may also want to consider its competitors.
152.40% Upside
BioCryst Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, BioCryst Pharmaceuticals's Price has grown by 100.00%, from $0.00 to $0.00. For the next year, analysts are expecting Fair Value to reach $4.48 – an increase of 100.00%. Over the next seven years, experts predict that Fair Value will grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CSL Stock Forecast | CSL | Outperform |
12
|
$278.45 | Buy/Sell | $205.51 | -27.04% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Buy |
4
|
¥4.77k | Buy/Sell | ¥5.24k | 21.70% |
| 4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.09k | Buy/Sell | ¥4.74k | 11.25% |
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$82.17 | Buy/Sell | $111.56 | 33.87% |
| 4507 Stock Forecast | Shionogi & | Outperform |
18
|
¥7.15k | Buy/Sell | ¥7.12k | 11.92% |
BioCryst Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last three years, BioCryst Pharmaceuticals's Revenue has grown by 1760.81%, from $17.81M to $331.41M. For the next year, analysts are expecting Revenue to reach $415.52M – an increase of 25.38%. Over the next seven years, experts predict that Revenue will grow by 209.18%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$41.84 | Buy/Sell | $55.60 | 43.88% |
| NTLA Stock Forecast | Intellia Therapeutics | Outperform |
8
|
$20.02 | Buy/Sell | $75.84 | 249.65% |
| PHARM Stock Forecast | Pharming Group N.V. | Buy |
16
|
0.88€ | Buy/Sell | 1.85€ | 132.95% |
.jpg)
BioCryst Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
BioCryst Pharmaceuticals's EBITDA has decreased by 41.34% In the last three years, from $-174.01M to $-102.07M. In the following year, the 1 analysts surveyed believe that BioCryst Pharmaceuticals's EBITDA will decrease by 41.56%, reaching $-59.65M. According to professionals, by 2030, BioCryst Pharmaceuticals's EBITDA will have decreased by 99.75%, falling down to $-256.64k.
BioCryst Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
In the last three years, BioCryst Pharmaceuticals's EBIT has decreased from $-174.76M to $-103.71M – a 40.66% drop! The next year, 7 experts forecast that BioCryst Pharmaceuticals's EBIT will decrease by 52.72%, reaching $-49.03M. In 2030, professionals predict that BioCryst Pharmaceuticals's EBIT will decrease by 633.60%, reaching $553.40M.
BioCryst Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, BioCryst Pharmaceuticals's EPS has grown by 100.00%, from $-1.09 to $0.00. For the next year, analysts are expecting EPS to reach $-0.60 – an increase of 100.00%. Over the next seven years, experts predict that EPS will grow by 100.00%.
Site Navigation
.jpg)